{"id":"60c9ffb6-30f4-5781-bfde-43129a198276","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-cyp2c8-and-the-r-hand","predicate":"limits","statement":"The CYP2C8*3 allele influenced the pharmacokinetics of R-ibuprofen in a gene-dose manner, with plasma half-life after 400 milligrams of 2.0 hours in CYP2C8*1/*1, 4.2 hours in *1/*3 and 9.0 hours in *3/*3 individuals, alongside significant trends in area under the curve and clearance, and the allele frequency of 0.17 in this Spanish Caucasian population was higher than reported elsewhere and was associated with CYP2C9*2 at 2.4-fold the expected frequency.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"b4c7b935-fe77-5e94-9af5-4f0e9514cc02","mechanism_event_label":"A common variant makes the R half linger more than four times as long.","subject":{"id":"6423d5bc-b276-5181-b399-c9d72839d421","slug":"cyp2c8-star3","display_name":"The CYP2C8*3 variant allele","entity_type_key":"protein_state"},"object":{"id":"07a563b8-3005-5217-9cc9-b76365f062c7","slug":"r-ibuprofen","display_name":"R(-)-ibuprofen","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"b4c7b935-fe77-5e94-9af5-4f0e9514cc02","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-cyp2c8-and-the-r-hand-event","event_type":"observed_intervention","label":"A common variant makes the R half linger more than four times as long.","description":"The CYP2C8*3 allele influenced the pharmacokinetics of R-ibuprofen in a gene-dose manner, with plasma half-life after 400 milligrams of 2.0 hours in CYP2C8*1/*1, 4.2 hours in *1/*3 and 9.0 hours in *3/*3 individuals, alongside significant trends in area under the curve and clearance, and the allele frequency of 0.17 in this Spanish Caucasian population was higher than reported elsewhere and was associated with CYP2C9*2 at 2.4-fold the expected frequency.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"eb6d83d8-65fd-5cb0-a8e2-b0bb74506200","slug":"cyp2c8","display_name":"Human cytochrome P450 2C8","entity_type_key":"protein"},"role":"affected_enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"c96f78f4-5bca-5867-9ac1-652891d40aa0","slug":"cyp2c9","display_name":"Human cytochrome P450 2C9","entity_type_key":"protein"},"role":"linked_gene","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6423d5bc-b276-5181-b399-c9d72839d421","slug":"cyp2c8-star3","display_name":"The CYP2C8*3 variant allele","entity_type_key":"protein_state"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"07a563b8-3005-5217-9cc9-b76365f062c7","slug":"r-ibuprofen","display_name":"R(-)-ibuprofen","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ibuprofen-research/15606441.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9\", \"start_char\": 0, \"end_char\": 1795, \"text_sha256\": \"60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Genotype screening of 355 Spanish Caucasians with pharmacokinetics in 25 individuals grouped by CYP2C8 genotype","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"400 milligrams ibuprofen, with R-ibuprofen disposition followed by genotype","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A clear gene-dose effect on the enantiomer that CYP2C9 does not handle. One population, and 25 individuals across the genotype groups.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A common variant makes the R half linger more than four times as long.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ibu-p15606441] The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15606441/ DOI: 10.1111/j.1365-2125.2004.02183.x","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Plasma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"90938abb-79a9-53af-8ce9-2e00e0a0d75c","evidence_kind":"source_excerpt","locator":"Lines 227-238","start_line":227,"end_line":238,"excerpt":"### ibu-cyp2c8-and-the-r-hand\nThe CYP2C8*3 allele influenced the pharmacokinetics of R-ibuprofen in a gene-dose manner, with plasma half-life after 400 milligrams of 2.0 hours in CYP2C8*1/*1, 4.2 hours in *1/*3 and 9.0 hours in *3/*3 individuals, alongside significant trends in area under the curve and clearance, and the allele frequency of 0.17 in this Spanish Caucasian population was higher than reported elsewhere and was associated with CYP2C9*2 at 2.4-fold the expected frequency.\nCondition category: normal\nnutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.\nplain_language: A common variant makes the R half linger more than four times as long.\norganism: Human\ntissue_or_cell_type: Plasma\nexperimental_model: Genotype screening of 355 Spanish Caucasians with pharmacokinetics in 25 individuals grouped by CYP2C8 genotype\nlimitations: A clear gene-dose effect on the enantiomer that CYP2C9 does not handle. One population, and 25 individuals across the genotype groups.\nexposure: 400 milligrams ibuprofen, with R-ibuprofen disposition followed by genotype\nevidence_span: {\"source_cache\": \"artifacts/ibuprofen-research/15606441.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9\", \"start_char\": 0, \"end_char\": 1795, \"text_sha256\": \"60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9\"}\n[ibu-p15606441] The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15606441/ DOI: 10.1111/j.1365-2125.2004.02183.x","model_system":"Genotype screening of 355 Spanish Caucasians with pharmacokinetics in 25 individuals grouped by CYP2C8 genotype","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ibu-p15606441] The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15606441/ DOI: 10.1111/j.1365-2125.2004.02183.x","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"31c4939d-f520-55c0-973b-224743caf245","stable_key":"import-3238e4f0-8d45-5c72-8624-6e9a8b20527c","title":"Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"cc2b388178f97f5906b66ecbe441fc5c86d51fd645947c5260fb0b4bdb4bcd21","revision_id":"0b4e5c65-05d3-5430-a4cd-8d6a03647dcb","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}